BOSTON and TAIPEI, Taiwan, June
23, 2014 /PRNewswire/ -- PAREXEL International (NASDAQ:
PRXL), a leading global biopharmaceutical services organization,
today announced that it has been named the 2014 Best Performing CRO
in Taiwan for its innovative drug
development strategies and healthcare industry leadership. PAREXEL
received the award in May from the Foundation of Medical
Professionals Alliance in Taiwan
(FMPAT) during the Taiwan Biotechnology Trend and Challenges
conference.
"PAREXEL applies its scientific expertise and innovative
approaches to reducing clinical trial complexity to help create
greater opportunities for clinical research in Taiwan and across the region," said
Albert Liou, PAREXEL Vice Chairman,
Asia Pacific. "We appreciate this
recognition of our ongoing commitment to simplifying drug
development for our customers and supporting their efforts to
prevent and cure disease."
Since 1999, PAREXEL has provided drug developers in Taiwan with a broad range of clinical research
and consulting services, as well as innovative technology
solutions. Two years ago, the Company formed an alliance with
National Taiwan University Hospital to strengthen its ability to
meet customer demand for end-to-end services in this rapidly
growing market.
"PAREXEL has a strong presence to support both international,
multi-center trials that include APAC as well as region and
country-specific needs," said Mark A.
Goldberg, M.D., President and Chief Operating Officer,
PAREXEL. "With 4,400 employees in 23 locations across 12 countries
in the region, PAREXEL offers an unparalleled infrastructure to
support customers across the entire development continuum."
Founded in 1992, FMPAT has united medical and health
professionals, and devoted itself to the promotion of health and
dignity of society and citizens in Taiwan. The foundation is a pioneer in
clinical research training programs, medical ethics and related
policy advocacy. For more information, visit www.mpat.org.tw.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of knowledge-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL operates in 75 locations in 50
countries around the world, and has 15,335 employees. For
more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL and "Your Journey. Our Mission." are trademarks or
registered trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more
fully in the section entitled "Risk Factors" of the Company's
Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 as filed with the Securities and
Exchange Commission (SEC) on May 2,
2014, which "Risk Factors" discussion is incorporated by
reference in this press release. The Company specifically
disclaims any obligation to update these forward-looking statements
in the future. These forward-looking statements should not be
relied upon as representing the Company's estimates or views as of
any date subsequent to the date of this press release.
Contacts:
Diana Martin,
Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
SOURCE PAREXEL International